Molecular Analysis of Breast Cancer

Breast Cancer Clinical Trial

Official title:

Molecular Analysis of Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00569049
• Other study ID #: SU-11052007-799
• Secondary ID: 1028313-100-JAAC
• Status: Active, not recruiting
• Start date: May 1996
• Est. completion date: May 2050

Study information

• Verified date: February 2023
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a research-based study that is looking at the biologic features of breast tissue, lymph node tissue, or blood in order to study breast cancer development growth, and spread. Through tissue and/or blood samples we hope to gain further knowledge and understanding of how to improve diagnosis and treatment of breast cancer by identifying the molecular markers that predict clinical outcome and response to therapy.

Description:

The tissue obtained in this protocol will be used for genome-wide examination of DNA, RNA expression profiling, proteomic analyses, isolation and analyses of normal and cancer stem cells, isolation and analyses of circulating tumor cells, possible analyses of immune cells, and possible analyses of serum factors. The tissue may also be used to develop patient-specific cell culture models or mouse xenograft models of breast cancer for biologic study of tumor progression and metastases and for therapeutic testing. In general, the tissue will be used in studies that will molecularly classify tumors, identify prognostic markers, identify potential therapeutic markers, identify potential treatment targets, and help us better understand the biology and specific role played by different tumor cells in the metastatic process.

The ultimate goal is to use molecular analyses to improve the diagnosis and treatment of breast cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 99999
• Est. completion date: May 2050
• Est. primary completion date: May 2050
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:People eligible for this study include anyone older than 18 years who is undergoing one of the following procedures: core needle or surgical breast biopsy, lumpectomy, mastectomy, axillary lymph node surgery, breast reduction surgery, or ductal lavage or ductoscopy. Patients who have had breast cancer in the past who are currently free of disease or who have a breast cancer recurrence are also eligible. All patients who participate must be able to understand and sign the informed consent. Although most patients will be female, any males undergoing the above procedures are also eligible for this study. Exclusion Criteria:Any patient who is less than 18 years old, who is unable to understand the informed consent, or not undergoing the above procedures will be excluded from this research.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Cancer Early Stage Breast Cancer (Stage 1-3)
• Breast Cancer Non-invasive Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• breast tissue, lymph node tissue or blood
Molecular Analyses of samples

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (5)

Lead Sponsor	Collaborator
Stanford University	Breast Cancer Research Foundation, California Breast Cancer Research Program, National Institutes of Health (NIH), University of California

Country where clinical trial is conducted

United States,